Skip to content
Lunsumio(mosunetuzumab)
Lunsumio (mosunetuzumab) is an antibody pharmaceutical. Mosunetuzumab was first approved as Lunsumio on 2022-06-03. It is used to treat follicular lymphoma in the USA. It has been approved in Europe to treat follicular lymphoma. It is known to target B-lymphocyte antigen CD20.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Lunsumio
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mosunetuzumab
Tradename
Proper name
Company
Number
Date
Products
Lunsumiomosunetuzumab-axgbGenentechN-761263 RX2022-12-22
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
lunsumioBiologic Licensing Application2022-12-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
follicular lymphoma—D008224C82
Agency Specific
FDA
EMA
Expiration
Code
mosunetuzumab, Lunsumio, Genentech, Inc.
2029-12-22Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.9671——10
Follicular lymphomaD008224C82371——10
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell lymphomaD01639325———7
Large b-cell lymphoma diffuseD016403C83.333———5
B-cell chronic lymphocytic leukemiaD015451C91.122———3
B-cell lymphoma marginal zoneD018442C88.4—1———1
Hodgkin diseaseD006689C81—1———1
LymphomaD008223C85.9—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M321————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMOSUNETUZUMAB
INNmosunetuzumab
Description
Mosunetuzumab, sold under the brand name Lunsumio, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1905409-39-3
RxCUI—
ChEMBL IDCHEMBL4297788
ChEBI ID—
PubChem CID—
DrugBankDB15434
UNII IDLDJ89SS0YG (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
931
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Q13963
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 268 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lunsumio
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
66 adverse events reported
View more details